Physician profile
Krista E Mcginnis
NPI 1083214043
$1,065.93
in general payments reported to CMS, 2019-2025
14 companies · $145 in 2025
The $145 reported for 2025 was less than what a typical Psychiatric/Mental Health, Child & Family provider received nationally (typical 2025 total: $178).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $75.85 · 2024: $845 · 2025: $145.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,066.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,065.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $175.16 | 2023-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $165.87 | 2023-2024 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $157.25 | 2024 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Collegium Pharmaceutical, INC. | $120.62 | 2025 | Jornay Pm |
| Lundbeck LLC | $82.28 | 2024 | Rexulti |
| Corium, LLC | $73.40 | 2024 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $68.40 | 2024 | Austedo Xr |
| Vertical Pharmaceuticals, LLC | $47.02 | 2024 | Relexxii |
| Ironshore Pharmaceuticals INC. | $35.46 | 2024 | |
| Neurocrine Biosciences, INC. | $32.46 | 2024 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $30.62 | 2024 | Trintellix |
| Alkermes, INC. | $29.24 | 2023 | Aristada, Lybalvi |
| Axsome Therapeutics, INC. | $24.59 | 2025 | Auvelity |
| Noven Therapeutics, LLC | $23.56 | 2024 | Secuado, Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Krista Mcginnis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.